Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

 
• By Joseph Haas
  
Cancer
Amgen thinks Five Prime's bemarituzumab offers utility in various tumor types
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business